Skip to main content
Premium Trial:

Request an Annual Quote

Becton Dickinson Said Fiscal Q2 Revenues Climb 9 Percent; Diagnostic Segment Leads Growth

NEW YORK , April 27 (GenomeWeb News) -  Becton Dickinson today reported $1.4 billion in total fiscal second-quarter revenues, a 9-percent increase from the same quarter one year ago.

 

Revenues were up across BD's Medical, Diagnostics, and Biosciences segments, and BD attributed further revenue increase to foreign currency translation, particularly the euro.

 

Diagnostics led the growth with a 12-percent increase over the comparable period last year, while Biosciences and medical grew by 9 percent and 8 percent respectively.

R&D spending in the quarter rose to $66 million from $60.2 million in the second quarter of 2004.

Net earnings increased to $188 million, or $.74 per basic share, from $165 million, or $.65 per share, during the second quarter of FY'05.

Cash and cash equivalents were not provided.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.